羅珊 周和玲

【摘 要】目的：探究分析口服免疫營(yíng)養(yǎng)制劑對(duì)肺癌胸腔鏡術(shù)后患者生活質(zhì)量的影響。方法：選取我科2018年11月-2019年3月胸腔鏡手術(shù)的肺癌患者102例作為研究對(duì)象，隨機(jī)數(shù)字法分為觀(guān)察組和對(duì)照組各51例。對(duì)照組術(shù)后給與常規(guī)的護(hù)理，觀(guān)察組術(shù)后給與常規(guī)護(hù)理輔以口服免疫營(yíng)養(yǎng)制劑愈素（Ⅱ）ω至術(shù)后一月，分別對(duì)兩組患者術(shù)后一周，術(shù)后一月，術(shù)后三月進(jìn)行生活質(zhì)量比較。結(jié)果：兩組患者術(shù)后一周生活質(zhì)量比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P﹥0.05），術(shù)后一月觀(guān)察組生活質(zhì)量?jī)?yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P﹤0.05），術(shù)后三月觀(guān)察組生活質(zhì)量顯著高于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P﹤0.01）。結(jié)論：口服免疫營(yíng)養(yǎng)制劑對(duì)肺癌胸腔鏡手術(shù)患者術(shù)后一周生活質(zhì)量無(wú)明顯改善，但對(duì)術(shù)后一月及以后的生活質(zhì)量有明顯的提高。

【關(guān)鍵詞】免疫營(yíng)養(yǎng)制劑;肺癌;胸腔鏡;生活質(zhì)量

Abstract：Objective ?To investigate the effect of oral immunonutrition on the quality of life of lung cancer patients after thoracoscopic surgery. Methods ?102 lung cancer patients underwent laparoscopic surgery from November 2018 to March 2019 in our department were enrolled. The randomized digital method was divided into observation group and control group. The control group received routine nursing after operation. The observation group was given routine nursing supplemented with oral immunonutrition preparations to the first month after surgery.Comparing the quality of life of the two groups. Results ?There was no significant difference in the quality of life between the two groups . The quality of life in the observation group was better than that in the control group in the first month after operation. The difference was statistically significant . The quality of life of the observation group was significantly higher than that of the control group， and the difference was statistically significant . Conclusion ?Oral immunonutrient preparations have no significant improvement in the quality of life in patients undergoing thoracic surgery for lung cancer， but the quality of life in the first month and beyond is significantly improved.

Key words： immunonutrient preparation; lung cancer; thoracoscopic; quality of life

【中圖分類(lèi)號(hào)】R574【文獻(xiàn)標(biāo)識(shí)碼】B【文章編號(hào)】1672-3783（2020）11-33--02

肺癌是我國(guó)發(fā)病率第一的惡性腫瘤，也是全國(guó)惡性腫瘤死亡第一的癌癥[1]。研究結(jié)果表明[2]：肺癌患者常發(fā)生不同程度的營(yíng)養(yǎng)不良，且機(jī)體免疫功能損傷加 劇了患者體內(nèi)營(yíng)養(yǎng)的流失，使其體內(nèi)營(yíng)養(yǎng)狀況進(jìn)一步惡化，嚴(yán)重影響了患者的手術(shù)效果及術(shù)后生存質(zhì)量。為了進(jìn)一步了口服免疫營(yíng)養(yǎng)制劑對(duì)肺癌術(shù)后患者生活質(zhì)量的影響，我科于2018年11月至2019年3月對(duì)臨床肺癌胸腔鏡手術(shù)患者開(kāi)展了臨床觀(guān)察。

1 研究對(duì)象與方法

1.1 研究對(duì)象

選取我科2018年11月-2019年3月胸腔鏡手術(shù)的肺癌患者102例作為研究對(duì)象。其中男性62例，女性40例，隨機(jī)數(shù)字法分為觀(guān)察組和對(duì)照組各51例。試驗(yàn)入選標(biāo)準(zhǔn)：病理學(xué)診斷為肺癌特征;癌細(xì)胞無(wú)轉(zhuǎn)移;腫瘤處于Ⅰ-Ⅲ期;無(wú)其他手術(shù)禁忌。排除精神類(lèi)疾病、其他心腦血管及免疫系統(tǒng)疾病。均知情并簽署同意書(shū)。兩組患者的一般資料無(wú)差異。具體見(jiàn)下表1.

1.2 方法

對(duì)照組給與常規(guī)護(hù)理，觀(guān)察組術(shù)后給與常規(guī)護(hù)理輔以口服免疫營(yíng)養(yǎng)制劑愈素（Ⅱ）ω至術(shù)后一月。對(duì)兩組患者術(shù)后一周、術(shù)后一月、術(shù)后三月采用QLQ-C30量表進(jìn)行生活質(zhì)量評(píng)分[3-4]。評(píng)分越高說(shuō)明患者術(shù)后生活質(zhì)量越好。且對(duì)患者進(jìn)行VAS和LCSS評(píng)分，VAS和LCSS評(píng)分越低說(shuō)明生活質(zhì)量越高[4]。

1.3 統(tǒng)計(jì)學(xué)分析

試驗(yàn)數(shù)據(jù)采用統(tǒng)計(jì)軟件SPSS 16.0進(jìn)行分析，計(jì)量資料用t檢驗(yàn)，計(jì)數(shù)資料用χ2檢驗(yàn)。以 P<0.05為差異有統(tǒng)計(jì)學(xué)意義。

2 結(jié)果

2.1 生活質(zhì)量對(duì)比